Liad Whatstein & Co. Law Office regularly advises global pharmaceutical companies on high-stakes patent litigation and prosecution, alongside related regulatory and transactional matters. The practice is also noted for its work on life cycle management strategies for major pharmaceutical products, as well as licensing arrangements and broader commercial transactions within the life sciences sector. The team is co-led by renowned IP litigator Liad Whatstein and Amira Mangelus, who acts in life sciences-related patent disputes. Oren Weiner is a patent term extension expert, who assists with pharmaceutical product management issues.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Sector knowledge
Key clients
- Novartis
- Sanofi
- Merck & Co
- Pfizer
- Bristol Myers Squibb
- Takeda
- Regeneron
- Abbott
- Bayer
- Astellas
- Alkermes
- UCB Pharma
Work highlights
Representing Pfizer in patent proceedings with respect to Pfizer’s blockbuster drugs, Nurtec (Rimegepant) and Vyndaqel (Tafamidis), such proceedings involving complex chemistry, formulation technology and drug pharmacokinetics issues.
Representing Merck in patent proceedings against Halozyme, in relation to the new formulation of Keytruda (anti-cancer drug).
Acting for the State of Israel in litigation against Teva, which concerns a new version of Copaxone, a drug that is based on technology developed at a government-owned hospital.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Liad Whatstein; Amira Mangelus
Other key lawyers
Oren Weiner